Compare Medpace Holdings Inc (MEDP) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Wendys Co — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Wendys Co trades at $8.66 (market cap $1.44B). The key difference: Medpace Holdings Inc is far larger — about 11.7× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | WEN | |
|---|---|---|
Market Cap | $16.90B | $1.44B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $10.68 |
52-Week Low | $393.42 | $6.17 |
Enterprise Value | $16.52B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Wendy's (WEN) stock is trading at $8.57, up 17.4% in 24 hours, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.18, beating expectations, but faces challenges including a 50% dividend cut, withdrawn 2026 outlook, and declining U.S. same-store sales as Burger King overtakes it as the second-largest U.S. burger chain. Financial metrics show a P/E of 11.44 and ROE of 108.04%, but net income margin has fallen to 5.72% for 2026.
The outlook is cautious; while valuation appears reasonable and recent earnings beats are positive, significant operational headwinds, high debt, and intense competition pose risks. Analyst sentiment is mixed with a majority Hold rating, reflecting uncertainty around the new CEO's turnaround plan. Investment opportunity hinges on successful execution of strategic initiatives to restore growth and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
